Cargando…

Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity

BACKGROUND: Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. OBJECTIVES: Increased appreciation of heterogeneity in fibro...

Descripción completa

Detalles Bibliográficos
Autores principales: Firl, Christina E. M., Halushka, Marc, Fraser, Nicola, Masson, Mala, Cuneo, Bettina F., Saxena, Amit, Clancy, Robert, Buyon, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117984/
https://www.ncbi.nlm.nih.gov/pubmed/37090702
http://dx.doi.org/10.3389/fimmu.2023.1114808
_version_ 1785028709885935616
author Firl, Christina E. M.
Halushka, Marc
Fraser, Nicola
Masson, Mala
Cuneo, Bettina F.
Saxena, Amit
Clancy, Robert
Buyon, Jill
author_facet Firl, Christina E. M.
Halushka, Marc
Fraser, Nicola
Masson, Mala
Cuneo, Bettina F.
Saxena, Amit
Clancy, Robert
Buyon, Jill
author_sort Firl, Christina E. M.
collection PubMed
description BACKGROUND: Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. OBJECTIVES: Increased appreciation of heterogeneity in fibroblasts encourages re-examination of existing models with the consideration of multiple fibroblast subtypes (and their unique functional differences) in mind. This study addressed fibroblast heterogeneity by examining expression of α-Smooth Muscle Actin (myofibroblasts) and of S100 Calcium-Binding Protein A4 (S100A4). METHODS: Using a previously established model of rheumatic scarring/fibrosis in vitro, supported by the evaluation of cord blood from cardiac-NL neonates and their healthy (anti-SSA/Ro-exposed) counterparts, and autopsy tissue from fetuses dying with cardiac-NL, the current study was initiated to more clearly define and distinguish the S100A4-positive fibroblast in the fetal cardiac environment. RESULTS: S100A4 immunostaining was observed in 4 cardiac-NL hearts with positional identity in the conduction system at regions of dystrophic calcification but not fibrotic zones, the latter containing only myofibroblasts. In vitro, fibroblasts cultured with supernatants of macrophages transfected with hY3 (noncoding ssRNA) differentiated into myofibroblasts or S100A4(+) fibroblasts. Myofibroblasts expressed collagen while S100A4(+) fibroblasts expressed pro-angiogenic cytokines and proteases that degrade collagen. Cord blood levels of S100A4 in anti-SSA/Ro-exposed neonates tracked disease severity and, in discordant twins, distinguished affected from unaffected. CONCLUSIONS: These findings position the S100A4(+) fibroblast alongside the canonical myofibroblast in the pathogenesis of cardiac-NL. Neonatal S100A4 levels support a novel biomarker of poor prognosis.
format Online
Article
Text
id pubmed-10117984
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101179842023-04-21 Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity Firl, Christina E. M. Halushka, Marc Fraser, Nicola Masson, Mala Cuneo, Bettina F. Saxena, Amit Clancy, Robert Buyon, Jill Front Immunol Immunology BACKGROUND: Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. OBJECTIVES: Increased appreciation of heterogeneity in fibroblasts encourages re-examination of existing models with the consideration of multiple fibroblast subtypes (and their unique functional differences) in mind. This study addressed fibroblast heterogeneity by examining expression of α-Smooth Muscle Actin (myofibroblasts) and of S100 Calcium-Binding Protein A4 (S100A4). METHODS: Using a previously established model of rheumatic scarring/fibrosis in vitro, supported by the evaluation of cord blood from cardiac-NL neonates and their healthy (anti-SSA/Ro-exposed) counterparts, and autopsy tissue from fetuses dying with cardiac-NL, the current study was initiated to more clearly define and distinguish the S100A4-positive fibroblast in the fetal cardiac environment. RESULTS: S100A4 immunostaining was observed in 4 cardiac-NL hearts with positional identity in the conduction system at regions of dystrophic calcification but not fibrotic zones, the latter containing only myofibroblasts. In vitro, fibroblasts cultured with supernatants of macrophages transfected with hY3 (noncoding ssRNA) differentiated into myofibroblasts or S100A4(+) fibroblasts. Myofibroblasts expressed collagen while S100A4(+) fibroblasts expressed pro-angiogenic cytokines and proteases that degrade collagen. Cord blood levels of S100A4 in anti-SSA/Ro-exposed neonates tracked disease severity and, in discordant twins, distinguished affected from unaffected. CONCLUSIONS: These findings position the S100A4(+) fibroblast alongside the canonical myofibroblast in the pathogenesis of cardiac-NL. Neonatal S100A4 levels support a novel biomarker of poor prognosis. Frontiers Media S.A. 2023-04-06 /pmc/articles/PMC10117984/ /pubmed/37090702 http://dx.doi.org/10.3389/fimmu.2023.1114808 Text en Copyright © 2023 Firl, Halushka, Fraser, Masson, Cuneo, Saxena, Clancy and Buyon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Firl, Christina E. M.
Halushka, Marc
Fraser, Nicola
Masson, Mala
Cuneo, Bettina F.
Saxena, Amit
Clancy, Robert
Buyon, Jill
Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
title Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
title_full Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
title_fullStr Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
title_full_unstemmed Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
title_short Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
title_sort contribution of s100a4-expressing fibroblasts to anti-ssa/ro-associated atrioventricular nodal calcification and soluble s100a4 as a biomarker of clinical severity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117984/
https://www.ncbi.nlm.nih.gov/pubmed/37090702
http://dx.doi.org/10.3389/fimmu.2023.1114808
work_keys_str_mv AT firlchristinaem contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT halushkamarc contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT frasernicola contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT massonmala contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT cuneobettinaf contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT saxenaamit contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT clancyrobert contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity
AT buyonjill contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity